GlassScriptPhysician profile
Kevin Mccarthy
NPI 1427184308
$4,992.29
in general payments reported to CMS, 2019-2025
19 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $554 · 2023: $515 · 2024: $1,157 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,739.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.36 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $565.18 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $550.74 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $492.07 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $370.90 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $368.71 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.88 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $235.04 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $205.09 | 2021-2022 | |
| Lundbeck LLC | $175.15 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $164.96 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $143.46 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $134.18 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Bausch Health US, LLC | $127.03 | 2023-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $91.27 | 2021-2024 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $23.84 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $18.83 | 2025 | Exxua |
| Allergan, INC. | $14.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.69 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.